JOHN L. HIGGINS - 28 Apr 2023 Form 4 Insider Report for BIO-TECHNE Corp (TECH)

Role
Director
Signature
/s/ Andrew Nick as Attorney-in-Fact for John L. Higgins pursuant to Power of Attorney previously filed
Issuer symbol
TECH
Transactions as of
28 Apr 2023
Net transactions value
-$34.76
Form type
4
Filing time
02 May 2023, 16:49:57 UTC
Previous filing
01 Feb 2023
Next filing
19 May 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TECH Common Stock Options Exercise $349,600 +16,000 +68% $21.85 39,360 28 Apr 2023 Direct
transaction TECH Common Stock Tax liability $349,635 -4,377 -11% $79.88 34,983 28 Apr 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TECH Stock Options (Right to Buy) Options Exercise $0 -16,000 -100% $0.000000* 0 28 Apr 2023 Common Stock 16,000 $21.85 Direct
holding TECH Stock Options (Right to Buy) 16,000 28 Apr 2023 Common Stock 16,000 $22.95 Direct
holding TECH Stock Options (Right to Buy) 17,040 28 Apr 2023 Common Stock 17,040 $21.84 Direct
holding TECH Stock Options (Right to Buy) 15,940 28 Apr 2023 Common Stock 15,940 $25.30 Direct
holding TECH Stock Options (Right to Buy) 12,500 28 Apr 2023 Common Stock 12,500 $31.26 Direct
holding TECH Stock Options (Right to Buy) 7,592 28 Apr 2023 Common Stock 7,592 $44.96 Direct
holding TECH Stock Options (Right to Buy) 8,044 28 Apr 2023 Common Stock 8,044 $50.41 Direct
holding TECH Stock Options (Right to Buy) 6,028 28 Apr 2023 Common Stock 6,028 $63.92 Direct
holding TECH Stock Options (Right to Buy) 2,532 28 Apr 2023 Common Stock 2,532 $128.81 Direct
holding TECH Stock Options (Right to Buy) 3,460 28 Apr 2023 Common Stock 3,460 $73.94 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests on the earlier of the one year anniversary of the grant date (10/27/22) or the date of Bio-Techne's 2023 annual meeting of shareholders.

Remarks:

On November 28, 2022, the Company completed a four-for-one stock split. All common stock amounts and exercise prices in the filing relating to securities acquired prior to November 28, 2022 have been adjusted to reflect the four-for-one stock split.